

July 29, 1966

Dr. Vincent Cremata
Chas. Pfizer and Co.
Groton, Connecticut 06340

Dear Vince,

Enclosed are the various reports which you requested concerning our studies of thiothixene. The summary report is our present draft copy and while I have checked it for technical accuracy, we would prefer that you consider it a preliminary draft and not as published material. You may, of course, use this internally or for the FDA, but I would request that you not refer to it until we have sent a definitive draft to you. My associates and I would be pleased for any comments or criticisms that you have.

We are enclosing case summaries, rating scale data and the clinical laboratory data.

Dr. Itil and I will review the P-5227 protocol this weekend and we will be in touch with you within a few days.

I would like to say that the staff have found thiothixene an effective and easy agent to use and it has been a pleasure working with it.

My best regards.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp